HUANG Liang,
ZHANG Ling-Li-*,
CHEN Li etc
.[J] Chinese Pharmaceutical Journal, 2013,V48(11): 1036-1037
��
[1]
PECK C, BARR W, BENET L, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics and toxikinetics in rational drug development. Clin Pharmacol Ther,1992,51:465-473.
[2]
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, FOOD AND DRUG ADMINISTRATION, CENTER FOR DRUG EVALUATION AND RESEARCH. Guidance for Industry: Population Pharmacokinetics(Draft Guidance).1997. http://www.fda.gov/cder/guidance/1852pk.htm.
[3]
SHI J, GUO T,XIA D Y, et al. Population pharmacokinetics of zolpidem tartrate tablets in healthy volunteers of five different nationalities in China.Chin Pharm J(�й�ҩѧ��־), 2011,46(11): 850-856.
[4]
WILLIAMS P J,ETTE E I.The role of population pharmacokinetics in drug development in light of the food and drug administration′s Guidance for industry: Population pharmacokinetics′.Clin Pharmacokinet,2000, 39(6): 385-395.
[5]
DUAN J Z. Applications of population pharmacokinetics in current drug labeling. J Clin Pharm Therapeut, 2007, 32(1):57-79.
2013, Vol. 48 
